In order to investigate the best morning insulin therapy to improve glycemic variability in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar.
In order to investigate the best morning insulin therapy to improve glycemic variability (GV) in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar. The results of the study were presented at The American Diabetes Association 77th Scientific Sessions.
The study enrolled 30 patients with type 2 diabetes, all of whom wore continuous glucose monitoring devices in admission after glucose levels (GL) were stabilized by morning insulins (long-acting and ultra-rapid). The patients were randomized to 2 groups: the first group received morning injections of 300 units per milliliter of the reference treatment, insulin glulisine and insulin glargine, on days 1 and 2 of treatment, followed by the same dose of insulin lispro and insulin glargine biosimilar on days 3 and 4. The second group received the biosimilar for the first 2 days of treatment, followed by the reference treatment on the final 2 days.
The patients received insulin injections at 8:00 am, and test meals were subsequently given. A day was defined as the period from 8:00 am to the following 8:00 am. On days 2 and 4, researches assessed the mean amplitude of glycemic excursion (MAGE) and the mean of daily differences (MODD). The researchers found that increased post-breakfast (PB) GL, PB glucose gradients, mean GL, standard deviation, M- value (12:00 am to 6:00 am), MAGE, and MODD were significantly lower in patients receiving the reference treatment than in the patients receiving the biosimilar treatment:
Pre-lunch and pre-breakfast GL were significantly lower in patients receiving the biosimilar treatment than in those receiving the reference. The difference in the highest PB GL between the groups was significantly correlated to 24-hour mean GL (r = 0.4, P = .03).
The researchers concluded that, compared with the biosimilar treatment, the reference treatment decreases PB GL, reducing the rate of rise, nocturnal and 24-hour GV and GL without causing hypoglycemia, and daily variance.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.